Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Bevacizumab with Chemotherapy in Gallbladder Cancer
NCT05757336Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in gallbladder cancer. Started Dec 2022; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT05757336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757336.